Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Therapuetics - Exam 3 > Anti-IL5, Anti-IL4/IL13, and PDE4 Inhibitors > Flashcards

Anti-IL5, Anti-IL4/IL13, and PDE4 Inhibitors Flashcards

1
Q

anti-IL5

A

blocks binding of IL-5 to the alpha chain of the IL-5 receptor complex
results in reduced production and survival of eosinophils

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

anti-IL5 drugs

A

mepolizumab (nucala)
reslizumab (cinqair)
benralizumab (fasenra)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

mepolizumab brand

A

nucala

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

mepolizumab (nucala) dosage forms

A

100mg/1mL auto-injector for home administration
100mg/1.2 mL after reconstituted with 1.2mL sterile water for injection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

reslizumab brand

A

cinqair

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

reslizumab (cinqair) dosage form

A

100mg/10mL solution for dilution in normal saline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

benralizumab brand

A

fasenra

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

benralizumab (fasenra) dosage forms

A

30mg/mL auto-injector for home administration
30mg/mL prefilled syringe

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

mepolizumab (nucala) dosing for 5-11 yos

A

approved for 6 and up
40mg sq every 4 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

mepolizumab (nucala) dosing for adults

A

100mg sq every 4 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

reslizumab (cinqair) dosing for adults

A

approved for 18 yos and up
3mg/kg IV once every 4 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

benralizumab (fasenra) dosing for adults

A

30 mg sq every 4 weeks for 3 doses then 30mg sq every 8 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

adverse effects of mepolizumab (nucala)

A

headache
injection site reactions
joint pain
herpes zoster infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

adverse effects of reslizumab (cinqair)

A

injection site reactions
muscle pain
increased creatinine phosphokinase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

adverse effects of benralizumab (fasenra)

A

injection site reactions
antibody development
headache
pharyngitis
fever

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

clinical pearls of mepolizumab (nucala)

A

precaution - anaphylaxis
available as an in-clinic or at-home injection
monitor for anaphylaxis before and after injection
indicated for add-on maintenance treatment of patients with severe asthma with an eosinophilic phenotype

17
Q

clinical pearls of reslizumab (cinqair)

A

boxed warning - anaphylaxis, malignancies
monitor for anaphylaxis before and after injection
indicated for add-on maintenance treatment of patients with severe asthma with an eosinophilic phenotype

18
Q

clinical pearls of benralizumab (fasenra)

A

precaution - anaphylaxis
available as in-clinic or at-home injection
indicated for add-on maintenance treatment of severe asthma in adults and children over 12 yos with an eosinophilic phenotype
acts on IL-5 receptor while others on IL-5

19
Q

Anti-IL4/IL13

A

blocks binding of IL-4 to reduce eosinophil trafficking and IgE reactions
also blocks IL-13 to reduce mucus secretion and airway remodeling
dupilumab (dupixent)

20
Q

dupilumab brand

A

dupixent

21
Q

dupilumab (dupixent) dosage forms

A

200mg/1.14 mL injection
300mg/2mL injection

22
Q

dupliumab (dupixent) dosing in adults

A

400 to 600mg sq initial dose followed by 200 to 300 mg every other week for maintenance
600 mg initial then 300 mg dosing used in patients with corticosteroid dependent asthma or atopic dermatitis

23
Q

adverse effects of dupliumab (dupixent)

A

injection site reactions
antibody development
joint pain
conjunctivitis

24
Q

clinical pearls of dupliumab (dupixent)

A

precaution - anaphylaxis
available in prefilled syringe for in-office or at-home administration
indicated as an add-on maintenance treatment in patients with moderate to severe asthma aged 12 yos and older with an eosinophilic phenotype or with oral corticosteroid dependent asthma

25
Q

phosphodiaesterase-4 inhibitors

A

inhibits PDE4 leading to increased cAMP
roflumilast (daliresp)

26
Q

roflumilast brand

A

daliresp

27
Q

roflumilast (daliresp) dosage form

A

tablets
250 mcg
500 mcg

28
Q

roflumilast (daliresp) dosing in adults

A

250 mcg qd for 4 weeks then 500 mcg qd
COPD only

29
Q

adverse effects of roflumilast (daliresp)

A

headache
weight loss
diarrhea
nausea

30
Q

monitor in roflumilast (daliresp)

A

liver function test
weight

31
Q

drug interactions in roflumilast (daliresp)

A

cyp3a4 (major)
cyp1a2 (minor)

32
Q

contraindications of roflumilast (daliresp)

A

child-pugh class B or C

Therapuetics - Exam 3 (12 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions